active cooperation with outstanding scientific talents from all over the world — fosun pharma welcomes prof. zhihong jiang to join its academician expert workstation
professor jiang zhihong, vice president of macau university of science and technology, said:
"i am very honored to be a member of the academician workstation of fosun pharma. fosun pharma takes innovation as the driving factor for development and has an international vision. i hope i can have in-depth cooperation with fosun pharma in theoretical research, technical exchanges, project cooperation, talent training and other aspects in the future, so as to realize benefit from industry-university-research cooperation."
dr. aimin hui, executive president of fosun pharma, president and chief medical officer of global r&d center, said:
"as an innovation-driven international pharmaceutical industry group, fosun pharma has connected with the world's outstanding scientists through diversified and multi-level cooperation modes such as independent r&d, cooperative development, license in and in-depth incubation. professor jiang zhihong is an internationally renowned expert in natural pharmaceutical chemistry, and his participation is of positive significance to fosun pharma's research and development in the corresponding field. in the future, fosun pharma will also continue to actively cooperate with outstanding scientists of china and other countries to conduct r&d cooperation and continuously improve its innovative r&d strength."
in 2014, shanghai fosun pharmaceutical (group) co., ltd. was approved to establish the "academician expert workstation", and academician ding jian of the chinese academy of engineering, researcher geng meiyu, researcher lin liping, researcher yuan xiurong, researcher zhang lei and researcher yao guangtao were invited to guide the research work. taking advantage of the small molecule innovator drug r&d technology platform, fosun pharma, together with academician ding jian's team skilled in r&d of anti-cancer drugs of protein kinase inhibitor, explored a research mode of "sharing risks, jointly owning patents and sharing achievements". in 2018, the academician workstation of fosun pharma was awarded the honorary title of "2018 model academician expert workstation" by china association for science and technology (cast), and the honorary title of "2018 excellent academician expert workstation" by shanghai academician expert workstation.
in addition, the academician workstation of fosun pharma has actively explored new cooperation modes, established an industry-university-research strategic cooperation relationship with shanghai university of tcm, actively developed and transformed new drug products, and accelerated the transformation of tcm scientific and technological achievements. in january 2020, science and technology commission of shanghai municipality awarded fosun pharma "shanghai key laboratory of stem cell therapy and drugs", and the academician workstation will focus on the research projects of stem cell therapy in future.
as a leading international pharmaceutical and health industry group in china, fosun pharma takes innovation and r&d as the core driver. in the first three quarters of 2021, fosun pharma invested rmb 3.151 billion in r&d, up 15.46% year on year, and r&d expenses were rmb 2.414 billion, up 28.54% year on year. as of june 30, 2021, fosun pharma had a total of 240 projects including innovator drugs, generic drugs, biosimilars and generic drugs, including 72 innovative drugs.